“下一代”CAR T细胞在实体瘤治疗中的研究进展

"Next Generation"CAR T cells for solid tumor treatment

嵌合抗原受体(CAR)T细胞疗法是一种新兴且有效的肿瘤免疫治疗。尽管靶向CD19的CAR T细胞已经在血液系统恶性肿瘤中取得了较好的临床疗效,但是对实体瘤的治疗仍面临巨大挑战。其中抗原识别、肿瘤抑制性微环境以及CAR T细胞的浸润、扩增和持久性是阻碍CAR T细胞发挥疗效的重要因素。为了解决这些问题,"下一代"CAR T细胞应运而生,这种新的策略运用基因工程进一步改造CAR T细胞以增强其功能。本文总结了"下一代"CAR T细胞通过改善对肿瘤的识别、浸润和持久性以及克服抑制性肿瘤微环境来增强CAR T细胞杀伤实体瘤的能力。

Chimeric antigen receptor(CAR)T cells therapy is a burgeoning and effective cancer immunotherapy.Although CD19 CAR T cells have achieved impressive clinical efficacy in hematological malignancies,the treatment of solid tumors still faces major challenges.Antigen recognition,tumor suppressive microenvironment,and the infiltration,expansion and persistence of CAR T cell are important factors that prevent CAR T cells from exerting efficacy.To address these obstacles,"Next Generation"CAR T cells have emerged,and this new strategy uses genetic engineering to further modify CAR T cells to enhance their function.This article summarizes the"next generation"CAR T cells enhance the ability of CAR T cells to kill solid tumors by improving identification,infiltration,persistence,and overcoming the suppressive tumor microenvironment.